Podcast

ASCRS 2020: Corneal CXL outcomes in children with progressive keratoconus

Author(s):

Alex Delaney-Gesing
Conferences|ASCRS

Soroosh Behshad, MD, MPH, of the Emory Eye Center, speaks with Ophthalmology Times'® David Hutton on the key takeaways from the presentation on, "Corneal crosslinking outcomes in children with progrssive keratoconus," during the 2020 ASCRS virtual meeting.

See more ASCRS coverage here

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game (Part 2)
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game? (Part 1)
Steven R. Sarkisian, Jr., MD, ABO, speaks about glaucoma at the 2025 ASCRS annual meeting
At the 2025 American Society of Cataract and Refractive Surgery (ASCRS) meeting, Seth Pantanelli, MD, speaks about the EyHance and enVista IOLs. Dr. Pantanelli is a professor of ophthalmology at Penn State College of Medicine in Hershey, Pennsylvania.
(Image credit: Ophthalmology Times) ASCRS 2025: Eric D. Donnenfeld, MD, on the effect of lifitegrast clinical signs and biomarkers in dry eye disease
(Image credit: Ophthalmology Times) ASCRS 2025: Amar Shah, MD, on why hyperosmolar tear film before and after cataract surgery matters
(Image credit: Ophthalmology Times) ASCRS 2025: Jason Bacharach, MD, on early-onset efficacy with perfluorohexyloctane in dry eye
Related Content
Children with ADHD may be less likely to develop myopia, study suggests
July 18th 2025

Children with ADHD may be less likely to develop myopia, study suggests

ROP: Treating and preventing blindness in preterm babies
October 18th 2021

ROP: Treating and preventing blindness in preterm babies

Study shows ceftriaxone found effective in treating congenital syphilis
June 11th 2025

Study shows ceftriaxone found effective in treating congenital syphilis

Evaluating safety, efficacy of TP03 for Demodex blepharitis treatment
July 26th 2021

Evaluating safety, efficacy of TP03 for Demodex blepharitis treatment

Ophthalmologists present data on perfluorohexyloctane eye drops
June 6th 2025

Ophthalmologists present data on perfluorohexyloctane eye drops

ViGeneron rebrands as VeonGen Therapeutics, announces rare pediatric disease designation for VG801
June 5th 2025

ViGeneron rebrands as VeonGen Therapeutics, announces rare pediatric disease designation for VG801

© 2025 MJH Life Sciences

All rights reserved.